Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about whether stopping Redensyl, unlike Minoxidil, allows you to maintain hair growth benefits. The user is considering Redensyl as an alternative to Minoxidil due to concerns about hair loss upon cessation of Minoxidil.

The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.

Redensyl improved hair thickness slightly with no side effects, but no regrowth. Minoxidil provided significant regrowth but caused facial side effects like puffiness.

The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.

The user has been using minoxidil, finasteride, dermastamping, and Nizoral for hair loss with initial success but is considering adding PRP due to slowed progress. Concerns about PRP include potential ineffectiveness and whether it could harm existing hair growth or interfere with current treatments.

RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

Exploring the effectiveness of redensyl, a hair loss treatment, compared to minoxidil and finasteride. People shared experiences using redensyl and products containing it, such as The Ordinary Hair Serum.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

RU58841, a hair loss treatment, is available on Amazon, but its legitimacy is questioned due to sketchy reviews and lack of lab reports. Some users report seeing results, while others experience negative side effects.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

RU58841, oral and topical minoxidil, finasteride, and ketoconazole shampoo led to significant hair regrowth, though some suspect a hair transplant. Concerns about RU58841's side effects, like anxiety and heart issues, were discussed.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation discusses whether a product recommended by a Portuguese pharmacist is the same as Minoxidil. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

RU58841 is being discussed for its effects on hair loss. The user has started using RU58841 with finasteride and is curious about its potential for hair maintenance or regrowth.

User asks if mixing RU58841 solution with Serioxyl is okay for better scalp coverage and worries about reduced effects.

RU58841 is discussed for hair loss treatment, with questions about its legitimacy from RUdirect. Minoxidil and finasteride are also mentioned as treatments.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. User feedback suggests 2-deoxy-D-ribose is ineffective.

A user is considering whether to continue using RU58841 or switch to hair system patches for a receding hairline, while already using finasteride, oral minoxidil, and microneedling. Another user suggests buying RU58841 in powder form to save money and notes the original poster's hair has significantly improved.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.